Close Menu
Honi Soit
    Facebook X (Twitter) Instagram
    Trending
    • Strawmanning in the chat at the July SRC Council
    • Folk Reimagined, East In Symphony at the Sydney Opera House
    • Graeme Turner’s ‘Broken’ assesses our ailing university sector
    • MAPW addresses USyd’s retreat from “obligation to promote peace” in open letter
    • 2025–26 State Budget Unpacked
    • Antisemitism review puts universities, festivals, and cultural centres under threat
    • Macquarie University axes Sociology, cuts more jobs & courses
    • UTS elects new Chancellor
    • About
    • Print Edition
    • Student Journalism Conference 2025
    • Writing Comp
    • Advertise
    • Locations
    • Contact
    Facebook Instagram X (Twitter) TikTok
    Honi SoitHoni Soit
    Wednesday, July 16
    • News
    • Analysis
    • Culture
    • Opinion
    • University
    • Features
    • Perspective
    • Investigation
    • Reviews
    • Comedy
    • Student Journalism Conference 2025
    Honi Soit
    Home»News

    USyd research shows promising results for treatment of incurable leukaemia

    USyd scientists publish new research that promises to aid in the fight against leukaemia
    By Oscar ChaffeyJuly 26, 2018 News 2 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Researchers at the University of Sydney have published promising preclinical data, which suggests that a new treatment known as IBL-202 may be effective in targeting the proliferation of chronic lymphocytic leukaemia (CLL).

    CLL is a type of blood cancer caused by the overproduction of a white blood cell type called B-lymphocytes in the bone marrow. Though treatments targeting B-cell production signalling pathways have advanced the treatment outcomes for patients diagnosed with CLL, the disease remains incurable.

    It is hoped that IBL-202 can selectively kill CLL cells even despite the hypoxic conditions of the tumour microenvironment, which allows cells in CLL to resist treatment and proliferate. The lead author of the study and expert in CLL research, Dr. Oliver Giles Best, wrote that, “collectively, this data demonstrates that dual inhibition (…) by IBL-202 may be an effective strategy for targeting CLL cells, particularly within the environmental niches known to confer drug-resistance.”

    While the University’s research is still in its preclinical stages and has, thus far, only used theoretical conditions mimicking the human CLL environment, the data is encouraging. Future testing in genuine clinical settings will be required before IBL-202 could be offered as a treatment to some of the 904,000 people globally who were affected by CLL in 2015.

    The new research, conducted in collaboration with the University, the Kolling Institute of Medical Research, Inflection Bioscience Ltd., and a member of the CLL Australian Research Consortium (CLLARC), was published in the most recent issue of the peer-reviewed British Journal of Haematology.

    The British start-up leading the research, Inflection Bioscience Ltd, is developing a variety of small biomolecule treatments like IBL-202 for treatment of haematological cancers such as CLL and other solid tumours that are treatment resistant. Whilst their treatments are all in preclinical development, the evidentiary outlook for their approach to treatment resistant diseases like CLL is optimistic.

    CLL Australian Research Consortium Inflection Bioscience Ltd. Kolling Institute of Medical Research leukaemia medical research

    Keep Reading

    Strawmanning in the chat at the July SRC Council

    MAPW addresses USyd’s retreat from “obligation to promote peace” in open letter

    Antisemitism review puts universities, festivals, and cultural centres under threat

    Macquarie University axes Sociology, cuts more jobs & courses

    UTS elects new Chancellor

    Jason Clare seeks replacement for ANU Chancellor Julie Bishop after $790,000 expense report

    Just In

    Strawmanning in the chat at the July SRC Council

    July 14, 2025

    Folk Reimagined, East In Symphony at the Sydney Opera House

    July 14, 2025

    Graeme Turner’s ‘Broken’ assesses our ailing university sector

    July 13, 2025

    MAPW addresses USyd’s retreat from “obligation to promote peace” in open letter

    July 13, 2025
    Editor's Picks

    Part One: The Tale of the Corporate University

    May 28, 2025

    “Thank you Conspiracy!” says Capitalism, as it survives another day

    May 21, 2025

    A meditation on God and the impossible pursuit of answers

    May 14, 2025

    We Will Be Remembered As More Than Administrative Errors

    May 7, 2025
    Facebook Instagram X (Twitter) TikTok

    From the mines

    • News
    • Analysis
    • Higher Education
    • Culture
    • Features
    • Investigation
    • Comedy
    • Editorials
    • Letters
    • Misc

     

    • Opinion
    • Perspective
    • Profiles
    • Reviews
    • Science
    • Social
    • Sport
    • SRC Reports
    • Tech

    Admin

    • About
    • Editors
    • Send an Anonymous Tip
    • Write/Produce/Create For Us
    • Print Edition
    • Locations
    • Archive
    • Advertise in Honi Soit
    • Contact Us

    We acknowledge the traditional custodians of this land, the Gadigal people of the Eora Nation. The University of Sydney – where we write, publish and distribute Honi Soit – is on the sovereign land of these people. As students and journalists, we recognise our complicity in the ongoing colonisation of Indigenous land. In recognition of our privilege, we vow to not only include, but to prioritise and centre the experiences of Indigenous people, and to be reflective when we fail to be a counterpoint to the racism that plagues the mainstream media.

    © 2025 Honi Soit
    • Privacy Policy
    • Terms
    • Accessibility

    Type above and press Enter to search. Press Esc to cancel.